---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-133476"
form_type: "8-K"
ticker: "BIIB"
cik: "0000875045"
company_name: "BIOGEN INC."
filed_at: "2023-05-03T23:59:59+00:00"
generated_at: "2026-06-16T02:08:34.091898+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# EU extends Tecfidera market exclusivity to Feb 2025

## Summary
- European Commission notified Biogen that Tecfidera's regulatory market protection extends to February 2, 2025.
- The extension provides longer exclusivity for Biogen's multiple sclerosis drug, delaying generic competition.
- Tecfidera contributed significant revenue; this decision supports Biogen's near-term cash flows.

## SEC filing metadata
- accession: 0001193125-23-133476
- form_type: 8-K
- ticker: BIIB
- cik: 0000875045
- company_name: BIOGEN INC.
- filed_at: 2023-05-03T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875045/000119312523133476/0001193125-23-133476-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875045/000119312523133476/d286559d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-133476
- JSON: https://secwatch.observer/filing/0001193125-23-133476.json
- Plain text: https://secwatch.observer/filing/0001193125-23-133476.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.